Biomarkers – Products

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications.

Residue analysis in food matrices is challenged by the presence of interfering co-extractables which can result in instrument contamination and system downtime. Experience the robustness of the SCIEX 7500+ system to help mitigate these challenges

This application note explores how automated workstations for tissue sample weighing and homogenization can increase efficiency and quality of results.

Assay automation makes cutting-edge research more accessible to labs.

Liquid biopsies are a minimally invasive alternative that can detect the presence of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) as tumor biomarkers.

New comprehensive biomarker panels equip physicians with clinically actionable insights for earlier, more accurate diagnosis.

Strategic collaborations in molecular residual disease monitoring of cancer and product launches in ddPCR portfolio advance corporate strategy in H1 2024.

Expansion of metabolite identification database accelerates insights, translation of findings for small molecule biomarker studies.

Your single solution for multimodal data​.
Uncover a true 6-base genome for unprecedented insights into current and future biological states. Access all four canonical bases and distinguish 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) from a single 5ng DNA sample, in a single experiment, with high accuracy.

Maximize rare variant detection with Twist's cfDNA Library Preparation Kit. Up 2X conversion yield of cfDNA libraries, high coverage libraries and robust performance, even with minimal sample input enables the confidence you value.